Human Evidence
Clinical and genetic datasets, RWD, published studies, functional screening and translational insights.
HUMAN EVIDENCE · MOLECULAR ENGINEERING · IMMUNE BIOLOGY
Engineering the next generation of small-molecule immune therapeutics.
Nuomune Biosciences combines human-supported biology, AI-assisted design, and differentiated small-molecule engineering to develop oral therapeutics for cancer immunotherapy and autoimmune diseases.
HE-ADP™Discovery platform
2Engineering strategies
3Featured programs
HUMAN-EVIDENCE-GUIDED PRECISION IMMUNE MODULATION ↓
01 / OUR PLATFORM
From human biology to proprietary oral therapeutics.
Our HE-ADP™ approach integrates evidence prioritization, AI-assisted molecular design, mechanistic validation, and translational development in a continuous learning cycle.
Molecular Engineering
Prodrug and mutual-codrug concepts, small-molecule design, linker chemistry, and PK/release optimization.
Mechanistic Validation
CD8⁺ T cells, Tregs, tumor immunity, checkpoint biology and autoimmune pathways.
Translational Development
Preclinical PK/PD, efficacy, safety, biomarkers and candidate-development readiness.
02 / TECHNOLOGY
Two engines. One focused immune therapeutics strategy.
Distinct chemistry and biology approaches, connected by shared translational capabilities.
ENGINE 01
Immunometabolic
Molecular Engineering
Designing oral small-molecule approaches to modulate immune metabolism and support T-cell function.
- Mutual-codrug and prodrug design
- Exposure and release optimization
- Rational checkpoint inhibitor combinations
FEATURED PROGRAM NMB-105
ENGINE 02
Immune Checkpoint
Homeostasis Modulation
Exploring small-molecule modulation of LRBA–CTLA-4 biology for context-dependent immune regulation.
- Checkpoint trafficking and stability
- Inhibitory and stabilizing approaches
- Oncology and autoimmune applications
FEATURED PROGRAMS NMB-201 · NMB-301
03 / DEVELOPMENT PIPELINE
Focused assets with distinct biological hypotheses.
Three featured research programs spanning immunometabolism and immune checkpoint homeostasis.
IMMUNOMETABOLISMPRECLINICAL
NMB-105
Inosine-based mutual-codrug
Designed to improve the therapeutic potential of inosine-associated immunometabolic biology, including exploration in combination with immune checkpoint inhibitors.
CHECKPOINT MODULATIONPRECLINICAL
NMB-201
LRBA / CTLA-4 pathway inhibitor
Investigating pathway inhibition as a potential approach to enhance antitumor immunity. Mechanistic selectivity and clinical utility require further validation.
CHECKPOINT MODULATIONPRECLINICAL
NMB-301
LRBA / CTLA-4 pathway stabilizer
Investigating stabilization of checkpoint homeostasis as a potential approach for immune regulation in autoimmune disease models.
Program names are proposed public-facing identifiers. All programs are investigational; no clinical efficacy or regulatory approval is implied. Development descriptions are subject to ongoing experimental confirmation.
04 / ABOUT NUOMUNE
Human evidence as the starting point. Engineering as the differentiator.
Nuomune Biosciences is building a small-molecule immune therapeutics portfolio that links human-supported biological insights to proprietary chemistry and rigorous preclinical validation.
Our discovery thesis is focused: improve drug-like properties, interrogate immune mechanisms, and pursue meaningful development milestones rather than treating early scientific signals as clinical proof.
Explore collaboration opportunities ↗05 / COLLABORATION
Advance immune therapeutics together.
We welcome conversations with research collaborators, strategic partners, and investors.
Contact Nuomune ↗Replace CONTACT_EMAIL_HERE with your official business email before publishing.